Department of Biomedical Science, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Postech-Catholic Biomedical Engineering Institute, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
J Neuroimmunol. 2014 Sep 15;274(1-2):20-7. doi: 10.1016/j.jneuroim.2014.06.001. Epub 2014 Jun 20.
We previously demonstrated that interferon β (IFN-β)-secreting mesenchymal stem cells (MSCs-IFN-β) strongly reduced the clinical severity of experimental autoimmune encephalomyelitis (EAE), compared with MSCs alone. Recently, minocycline ameliorates the clinical severity of multiple sclerosis (MS). Herein, we evaluated the effects of a combined treatment of MSCs-IFN-β and minocycline on EAE mice. The combined treatment significantly alleviated the clinical severity mainly by maintaining the integrity of blood-spinal cord barrier, in a manner likely involving inhibition of microvascular disruption, matrix metalloproteinases, neuroinflammation, and enhancement of immunomodulatory effects. Therefore, this combined treatment has the potential to improve the functional recovery of patients with MS.
我们之前的研究表明，与单独的间充质干细胞（MSCs）相比，分泌干扰素β（IFN-β）的间充质干细胞（MSCs-IFN-β）可显著减轻实验性自身免疫性脑脊髓炎（EAE）的临床严重程度。最近，米诺环素改善了多发性硬化症（MS）的临床严重程度。在此，我们评估了 MSCs-IFN-β 和米诺环素联合治疗对 EAE 小鼠的影响。联合治疗通过维持血脊髓屏障的完整性，显著缓解了临床严重程度，其机制可能涉及抑制微血管破坏、基质金属蛋白酶、神经炎症和增强免疫调节作用。因此，这种联合治疗有可能改善 MS 患者的功能恢复。
